Compare iShares China Large-Cap ETF (FXI) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares China Large-Cap ETF vs Neurocrine Biosciences Inc — how do they compare? iShares China Large-Cap ETF trades at $35.39, while Neurocrine Biosciences Inc trades at $151.32 (market cap $16.46B). Which is the better fit depends on your goals.
| FXI | NBIX | |
|---|---|---|
52-Week High | $41.75 | $185.50 |
52-Week Low | $31.59 | $123.10 |
Market Cap | — | $16.46B |
Sector | — | Health |
Enterprise Value | — | $16.48B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares China Large-Cap ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index designed to measure the performance of the largest companies in the Chinese equity market that trade on the Stock Exchange of Hong Kong and are available to international investors. The fund is non-diversified.
Read more on FXI →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
